VR 2076

Drug Profile

VR 2076

Alternative Names: ICS/LABA/LAMA inhaled triple therapy - Vectura; LABA/LAMA/ICS inhaled triple therapy- Vectura; SKP 2076; VR2076

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SkyePharma PLC
  • Developer Mundipharma International; Vectura
  • Class Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 04 Jan 2018 Mundipharma stops the development of VR 2076 for Asthma and Chronic obstructive pulmonary disease
  • 23 Dec 2016 VR 2076 licensed to Mundipharma and an undisclosed US company for Asthma and Chronic obstructive pulmonary disease
  • 23 Dec 2016 Vectura announces intention to submit regulatory application in the EU in late 2022 or early 2023
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top